-5%
- Epalrestat, the active ingredient in Neureliv, specifically inhibits aldose reductase and prevents the accumulation of sorbitol in nerve tissues. This mechanism helps alleviate symptoms and improves nerve dysfunction in patients with diabetic peripheral neuropathy.
Neureliv is indicated for the improvement of symptoms associated with diabetic peripheral neuropathy, including:
- Numbness and pain.
- Abnormality of vibration sense.
- Abnormal changes in heartbeat, particularly when high glycohemoglobin levels are noted.